Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

@article{Insinga2005InhibitorsOH,
  title={Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway},
  author={Alessandra Insinga and Silvia Monestiroli and Simona Ronzoni and Vania Gelmetti and Francesco Marchesi and Andrea Viale and Lucia Altucci and Clara Nervi and Saverio Minucci and Pier Giuseppe Pelicci},
  journal={Nature Medicine},
  year={2005},
  volume={11},
  pages={71-76}
}
Histone deacetylases (HDACs) regulate transcription and specific cellular functions, such as tumor suppression by p53, and are frequently altered in cancer. Inhibitors of HDACs (HDACIs) possess antitumor activity and are well tolerated, supporting the idea that their use might develop as a specific strategy for cancer treatment. The molecular basis for their selective antitumor activity is, however, unknown. We investigated the effects of HDACIs on leukemias expressing the PML-RAR or AML1-ETO… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 237 extracted citations

New and emerging HDAC inhibitors for cancer treatment.

The Journal of clinical investigation • 2014
View 6 Excerpts
Highly Influenced

Histone Deacetylase Inhibitors

View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia

M Higuchi
Cancer Cell 1, • 2002

Similar Papers

Loading similar papers…